RESEARCH

Publication Alert! Olaris publishes a paper in the Journal of Metabolites

May 17, 2020

Olaris' paper was recently published in the Journal of Metabolites. The paper demonstrates the reproducibility of non-uniform sampling 2D NMR in metabolomics. Thank you, Dr. Liz O'Day and Dr. Bo Zhang, for all the hard work. Link to the paper below.

Olaris Presents NMR-based Metabolomics Research at ENC!

March 09, 2020

Olaris' will be presenting a poster and giving a talk at the ENC! The Experimental NMR Conference features innovative research in NMR spectroscopy and Olaris is very excited to share our recent studies on the power of NUS 13C 1H HSQC NMR. See the poster below. 

Olaris Announces Findings from Exploratory Analysis of Biomarkers that Predict Patient Responsiveness to Trastuzumab Therapy

March 02, 2020

Olaris’ metabolite profiling platform and machine learning algorithms have the potential to accurately indicate whether HER2-positive metastatic breast cancer patients will respond to trastuzumab therapy.

Olaris Head of Metabolite Discovery, Dr. Bo Zhang, had a paper come out in the Journal of Proteome Research

February 28, 2020

Research Dr. Zhang contributed to was published in the Journal of Proteome Research. They developed a method to better identify lipid molecules through 2D NMR and COLMAR Lipids Web Server. 

Olaris Presents a Poster at the San Antonio Breast Cancer Symposium!

December 12, 2019

Olaris is thrilled to present at the SABCS! We are excited to learn from the world's top breast cancer oncologists and share the results of our recent study, "Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer." Learn more about our findings here. 

Dr. Bo Zhang, Olaris Head of Metabolite Discovery, had a paper come out in Analytical Chemistry!

December 11, 2019

"Accurate and Efficient Determination of Unknown Metabolites in Metabolomics by NMR-Based Molecular Motif Identification" discusses the new SUMMIT method to identify chemical classes of metabolites, a critical tool in understanding patient health and disease. Read the paper here!

Olaris Metabolite Scientist, Dr. Chandra Honrao, had a paper come out in Nature Research!

November 29, 2019

We are so proud of Dr. Honrao for his work in helping to discover a new antibiotic for Gram-negative pathogens, a notoriously difficult pathogen to target. In fact, the last development in antibiotics for Gram-negative bacteria was in the 1960s. The exciting discovery has the potential to be developed into new therapeutics. Read the paper here!

Olaris presents groundbreaking data ASCO 2019!

May 28, 2019

The Olaris Team gives poster presentation at the ASCO Annual Meeting on biomarker to optimize CDK4/6 treatment for breast cancer patients.

Paper: Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells

October 15, 2018

Cancer cells have altered bioenergetics, which contributes to their ability to proliferate, survive in unusual microenvironments, and invade other tissues. Changes in glucose metabolism can have pleomorphic effects on tumor cells. To investigate potential mechanisms responsible for the increased malignancy associated with altered glucose metabolism, we used Olaris technology  to identify glucose metabolites differentially produced in a highly malignant human triple-negative breast cancer (TNBC) cell line (BPLER) and a less malignant isogenic TNBC cell line (HMLER).

Are We There Yet? How and When Specific Biotechnologies Will Improve Human Health

May 24, 2018

From genome editing to precision medicine learn the details of how these biotechnologies are poised to transform health.

Please reload

Olaris, Inc

35 Gatehouse Drive

Waltham, Massachusetts

02451

e: info@olarisBoR.com

  • Grey LinkedIn Icon
  • Grey Facebook Icon

© 2019 Olaris, Inc